Zobrazeno 1 - 10
of 68
pro vyhledávání: '"Mitsuru, Kajiwara"'
Autor:
Jun Teishima, Daiki Murata, Kazuma Yukihiro, Yohei Sekino, Shogo Inoue, Tetsutaro Hayashi, Koji Mita, Yasuhisa Hasegawa, Masao Kato, Mitsuru Kajiwara, Masanobu Shigeta, Satoshi Maruyama, Hiroyuki Moriyama, Seiji Fujiwara, Akio Matsubara
Publikováno v:
Current Urology, Vol 17, Iss 1, Pp 52-57 (2023)
Abstract. Objectives. This study aimed to clarify the significance of therapeutic timing on the effectiveness of nivolumab for treating metastatic renal cell carcinoma. Marterials and methods. Fifty-eight patients with metastatic renal cell carcinoma
Externí odkaz:
https://doaj.org/article/ccdc446a8c8f4b7ea52feff951dbda31
Autor:
Jun Teishima, Daiki Murata, Shogo Inoue, Tetsutaro Hayashi, Koji Mita, Yasuhisa Hasegawa, Masao Kato, Mitsuru Kajiwara, Masanobu Shigeta, Satoshi Maruyama, Hiroyuki Moriyama, Seiji Fujiwara, Akio Matsubara
Publikováno v:
Current Urology, Vol 15, Iss 4, Pp 187-192 (2021)
Abstract. Background:. There are various alternative first-line therapeutic options besides tyrosine kinase inhibitors (TKIs) for metastatic renal cell carcinoma (mRCC). To inform therapeutic decision-making for such patients, this study aimed to ide
Externí odkaz:
https://doaj.org/article/84641c04523a4c029d5f563adab6a1ad
Autor:
Katsumaro Kubo, Masahiro Kenjo, Hideo Kawabata, Koichi Wadasaki, Mitsuru Kajiwara, Yoshiko Doi, Minoru Nakao, Hideharu Miura, Shuichi Ozawa, Yasushi Nagata
Publikováno v:
Journal of Medical Case Reports, Vol 15, Iss 1, Pp 1-8 (2021)
Abstract Background Few studies have assessed hydrogel spacer shrinkage during external-beam radiation therapy following brachytherapy for localized high-risk prostate cancer. This case presentation evaluated the changes in hydrogel spacer appearance
Externí odkaz:
https://doaj.org/article/dffa8fc0c7c14bdca207cfd7c429449e
Autor:
Kenshiro Takemoto, Yohei Sekino, Hiroyuki Kitano, Kenichiro Ikeda, Keisuke Goto, Keisuke Hieda, Tetsutaro Hayashi, Yasuhisa Hasegawa, Masao Kato, Yuichi Kadonishi, Mitsuru Kajiwara, Jun Teishima, Koji Mita, Satoshi Maruyama, Masanobu Shigeta, Nobuyuki Hinata
Publikováno v:
International Journal of Urology. 30:319-327
To evaluate the significance of both low and high body mass index (BMI) as a biomarker in first-line tyrosine kinase inhibitors (TKIs) for metastatic renal cell carcinoma (mRCC).The oncological outcome of 235 patients with mRCC treated with TKI from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::410f0dd7f3f4aafab9203f9ed0fc62ce
https://doi.org/10.1111/iju.15110
https://doi.org/10.1111/iju.15110
Autor:
Jun Teishima, Daiki Murata, Kazuma Yukihiro, Yohei Sekino, Shogo Inoue, Tetsutaro Hayashi, Koji Mita, Yasuhisa Hasegawa, Masao Kato, Mitsuru Kajiwara, Masanobu Shigeta, Satoshi Maruyama, Hiroyuki Moriyama, Seiji Fujiwara, Akio Matsubara
Publikováno v:
Current Urology. 17:52-57
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba5e12bf243af32e88fb14bacf29b2a1
https://doi.org/10.1097/cu9.0000000000000105
https://doi.org/10.1097/cu9.0000000000000105
Autor:
Jun Teishima, Keisuke Goto, Yohei Sekino, Koji Mita, Tetsutaro Hayashi, Yasuhisa Hasegawa, Masao Kato, Mitsuru Kajiwara, Masanobu Shigeta, Satoshi Maruyama, Yuichi Kadonishi, Seiji Fujiwara, Kanao Kobayashi, Kousuke Asano, Nobuyuki Hinata
Publikováno v:
International Urology and Nephrology. 54:1225-1232
The aim of this study was to investigate prognostic factors and to establish a prognostic model using them for upfront cytoreductive nephrectomy (CN) in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitor (IC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77609688c203485207582e7a07b5bd27
https://doi.org/10.1007/s11255-022-03157-w
https://doi.org/10.1007/s11255-022-03157-w
Publikováno v:
Asian Journal of Surgery, Vol 39, Iss 1, Pp 6-11 (2016)
Objective: Our objective was to compare the perioperative parameters of needle-assisted and conventional laparoendoscopic single-site adrenalectomy (LESS-A). Methods: We compared 23 patients undergoing needle-assisted LESS-A with 29 patients undergoi
Externí odkaz:
https://doaj.org/article/e868e7568d1445378ab7101c5917db84
Autor:
Yuki Kohada, Kazuma Yukihiro, Jun Teishima, Peter C. Black, Akio Matsubara, Keisuke Goto, Takashi Nishisaka, Kazuhiro Sentani, Mitsuru Kajiwara, Shinya Ohara, Wataru Yasui, Tetsutaro Hayashi, Shogo Inoue, Ryan S. Hsi
Publikováno v:
BJU International. 127:473-485
OBJECTIVES To assess the change in rates of recurrence-free survival (RFS) and progression-free survival (PFS) based on the duration of survival without recurrence or progression among patients with intermediate-risk (IR) non-muscle-invasive bladder
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c18dc73bae6ab4ef1fc25fd642bdab4e
https://doi.org/10.1111/bju.15209
https://doi.org/10.1111/bju.15209
Autor:
Kenichiro Ikeda, Kenshiro Takemoto, Akio Matsubara, Jun Teishima, Tetsutaro Hayashi, Shogo Inoue, Hirotaka Nagamatsu, Akihiro Goriki, Mitsuru Kajiwara, Yuki Kohada
Publikováno v:
Anticancer Research. 40:4787-4793
Background/aim Bladder cancer with histological variant (HV) has different morphological features from usual urothelial carcinoma (UC). The aim of this study was to evaluate the oncological outcomes of HV in patients with bladder cancer. Patients and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::faa20a3c8b0b1a1130c5f0f3a7e89ded
https://doi.org/10.21873/anticanres.14481
https://doi.org/10.21873/anticanres.14481
Autor:
Kenshiro Takemoto, Tetsutaro Hayashi, Ryan S. Hsi, Kohei Kobatake, Yohei Sekino, Hiroyuki Kitano, Kenichiro Ikeda, Keisuke Goto, Keisuke Hieda, Kazuhiro Sentani, Mitsuru Kajiwara, Takashi Nishizaka, Jun Teishima, Naohide Oue, Nobuyuki Hinata
Publikováno v:
Urologic Oncology: Seminars and Original Investigations. 40:539.e9-539.e16
Patients with histological variants (HV) of bladder cancer have more advanced disease and poorer survival rates than those with pure urothelial carcinoma (UC). Moreover, lymphovascular invasion (LVI) is an important biomarker after RNU in systematic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b1421c1a6a0750b7da47ded13a22b08
https://doi.org/10.1016/j.urolonc.2022.08.010
https://doi.org/10.1016/j.urolonc.2022.08.010